SPRING-2 the future of antiretroviral therapy. (Record no. 23124735)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01114 a2200325 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250516172439.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201401s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1474-4457 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1016/S1473-3099(13)70194-4 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Boyd, Mark A |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20140108 |
| 245 00 - TITLE STATEMENT | |
| Title | SPRING-2 the future of antiretroviral therapy. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | The Lancet. Infectious diseases |
| Date of publication, distribution, etc. | Nov 2013 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 908-9 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Letter; Comment |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | HIV Infections |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | HIV Integrase Inhibitors |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | HIV-1 |
| General subdivision | isolation & purification |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Heterocyclic Compounds, 3-Ring |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Oxazines |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Piperazines |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pyridones |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cooper, David A |
| 773 0# - HOST ITEM ENTRY | |
| Title | The Lancet. Infectious diseases |
| Related parts | vol. 13 |
| -- | no. 11 |
| -- | p. 908-9 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1016/S1473-3099(13)70194-4">https://doi.org/10.1016/S1473-3099(13)70194-4</a> |
| Public note | Available from publisher's website |
No items available.